Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 15Other neoplasm 1

Conditions

Precancerous Conditions 32Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma, Large-Cell, Immunoblastic 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia 12Burkitt Lymphoma 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Neoplasms, Plasma Cell 11Multiple Myeloma 11Monoclonal Gammopathy of Undetermined Significance 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Large Granular Lymphocytic 11Leukemia, Hairy Cell 11Immunoglobulin Light-chain Amyloidosis 11Waldenstrom Macroglobulinemia 10Thrombocythemia, Essential 10Primary Myelofibrosis 10Myeloproliferative Disorders 10Myelodysplastic Syndromes 10Leukemia, Myeloid, Acute 10Immunoblastic Lymphadenopathy 10Hodgkin Disease 10Polycythemia Vera 9Lymphoma, Large-Cell, Anaplastic 9Leukemia, Prolymphocytic 9

Interventions

Erlotinib Hydrochloride 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Barrett Esophagus × Other neoplasm × Clear all
NCT00566800 2013-09-17

Erlotinib in Treating Patients With Barrett Esophagus

National Cancer Institute (NCI)

Phase 1 Unknown
25 enrolled
GastrointestinalOther neoplasm

Barrett Esophagus, Esophageal Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡